SureTrader SureTrader SureTrader
Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

Here is the link to Germany DCVax Clinical

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
john1045 Member Profile
 
Followed By 30
Posts 2,369
Boards Moderated 0
Alias Born 06/09/11
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/23/2017 9:23:13 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 1/19/2017 4:58:32 PM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 1/10/2017 5:02:42 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 1/10/2017 5:01:52 PM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 12/30/2016 6:08:08 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 12/29/2016 4:31:56 PM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 12/29/2016 11:40:59 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/28/2016 7:01:33 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 12/28/2016 6:02:34 AM
Traders News Digs into the Biotech Space and Releases New Feature Profile "InvestorsHub NewsWire" - 12/20/2016 8:30:00 AM
(25) "Edgar (US Regulatory)" - 12/19/2016 6:06:04 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/9/2016 5:29:28 PM
NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed Glioblastoma Multiforme Brain Cancer "PR Newswire (US)" - 12/8/2016 2:04:00 PM
NW Bio Announces Decision to Voluntarily Withdraw from Nasdaq Listing and Begin Trading on OTC Market "PR Newswire (US)" - 12/7/2016 8:00:00 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 12/1/2016 4:20:39 PM
RT Minerals Corp. (TSX.V: RTM), High Grade Gold Norwalk Property, Drill Plan Ballard Lake Property "InvestorsHub NewsWire" - 11/22/2016 8:05:00 AM
NW Bio Announces Phase II Clinical Trial Program Combining DCVax®-L and Pembrolizumab (Keytruda®) for Colorectal Cancer "PR Newswire (US)" - 11/17/2016 8:15:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/14/2016 5:07:23 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/10/2016 4:36:27 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 11/9/2016 4:52:01 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/27/2016 10:35:46 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/25/2016 5:09:36 PM
NW BIO Announces Registered Direct Offering "PR Newswire (US)" - 10/21/2016 9:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/19/2016 5:30:05 PM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 10/19/2016 6:01:50 AM
john1045   Monday, 12/24/12 04:47:16 PM
Re: None
Post # of 97818 
Here is the link to Germany DCVax Clinical trials with an area I pasted from long report so they obviously are recruiting over there as of now....

http://translate.google.com/translate?hl=en&sl=de&u=http://www.uniklinik-duesseldorf.de/fileadmin/Datenpool/einrichtungen/universitaetstumorzentrum_id505/neu2012/Dateien/Klinische_Studien_UTZ_Duesseldorf.pdf&prev=/search%3Fq%3Ddcvax%26start%3D50%26hl%3Den%26sa%3DN%26tbo%3Dd%26biw%3D1366%26bih%3D586%26tbs%3Dqdr:w&sa=X&ei=I8nYULiqM7GH0QGx6oDACg&ved=0CGwQ7gEwCTgy

Page 11 of 23

Clinical trials in brain tumors


IND No. 10206

Glioblastoma (brain cancer)

Phase II clinical trial to evaluate DCVax-Brain, autologous dendritic cells pulsed with tumor lysate, for treatment

of glioblastoma multiforme.



A Phase II Clinical Trial Evaluating DCVax-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate for the Treatment of Glioblastoma

Multiforme

Your contact:

Prof. Dr. Michael Sabel

Michael.Sabel @ med.uni-duesseldorf.de



Page 12


Current clinical studies at University Cancer Center UTZ

University Cancer Center UTZ

Info Phone: 0211-8108200

at the University Hospital Dusseldorf

www.uniklinik-duesseldorf.de/utz

Stand: 01/2013

Page 12 of 23

Clinical trials in brain tumors

Fraunhofer Institute

Glioblastoma (brain cancer)

Phase II clinical study evaluating DCVax ®-L Brain autologous dendritic cells loaded with tumor lysate antigen for

Treatment of glioblastoma multiforme (GBM)

Clinical phase II trial to evaluate DCVax ®-L Brain autologous dendritic cells loaded with tumor lysate antigen for treatment of glioblastoma

multiforme (GBM)

Your contact:

Infoline

Tel: 0211-8108200

[email protected]



SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist